Core Insights - SINOCARE has successfully established a presence in the African market, exporting an average of 40,000 blood glucose monitoring devices and 40,000 boxes of test strips monthly, covering over 40 countries including Egypt, Nigeria, and Kenya [2] - The company began its expansion into Africa around 2017, facing initial challenges due to negative perceptions of Chinese products and strong competition from established Western brands [2][3] - SINOCARE's strategy focuses on product quality and affordability, exemplified by its blood glucose meter achieving a low error rate of ±3%, which helped it gain entry into the Algerian market [3] Market Dynamics - The demand for diabetes monitoring in Africa is increasing, with the World Health Organization predicting that there will be 60 million diabetes patients in sub-Saharan Africa by 2050, reflecting a compound annual growth rate of over 140% [4] - The company is set to launch its AI-driven "Aikan" series of Continuous Glucose Monitoring (CGM) products in Africa in 2024, which will allow users to monitor their blood glucose levels continuously via a connected app [3] - Challenges such as weak local infrastructure are being addressed by SINOCARE through offline storage and scheduled data uploads [4] Competitive Landscape - The acceptance of Chinese products in Africa is gradually improving, with increasing competition from other Chinese companies entering the market, which poses challenges for SINOCARE [4]

Core Viewpoint - The company participated in an online investor reception event, discussing its product offerings, stock management, digital transformation, and market conditions, particularly focusing on diabetes management products and strategies for growth in both domestic and international markets [1] Group 1: Investor Relations Activity - The investor relations activity was held on September 19, 2025, from 15:40 to 17:00 via the "Panorama Roadshow" website [1] - Key participants included the Deputy General Manager and Board Secretary, Zheng Jiyun, and Securities Affairs Representative, Xu Huiyu [1] Group 2: Product Layout - The company primarily focuses on diabetes and related chronic disease detection products, with its subsidiary Trividia Health, Inc. offering the "TRUE" series of blood glucose monitoring products and diabetes care items [1] Group 3: Stock Price and Market Management - In response to concerns about stock price declines during a bull market, the company confirmed normal operations and disclosed no undisclosed matters [1] - The company has initiated a "Quality and Return Dual Improvement" action plan since 2024 and has repurchased 4,824,900 shares for a total amount of approximately 99.92 million yuan as of August 31, 2025 [1] Group 4: Digital Transformation and Business Outlook - The company is enhancing its diabetes management ecosystem by deploying IoT technology and launching a smart diabetes management system [1] - The "Aikan Health" app is set to launch in the HarmonyOS NEXT application market in September 2024, with plans for further digital transformation and AI integration [1] Group 5: Tariff Impact - In the first half of 2025, the company reported revenue of approximately 226.37 million yuan, with 32.86% coming from the U.S. market [1] - The company noted that most U.S. revenue is generated from local production, thus not affected by "reciprocal tariffs," and has sufficient inventory to mitigate tariff impacts [1] Group 6: CGM Business - The company plans to refine its second and third-generation Continuous Glucose Monitoring (CGM) products based on FDA feedback and expedite new product IDE applications [1] - The company views domestic price competition as a natural phase of market development, with a focus on sustainable long-term growth despite short-term profitability impacts [1]